See more : Gencell Ltd (GNCLF) Income Statement Analysis – Financial Results
Complete financial analysis of Evolent Health, Inc. (EVH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evolent Health, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Alphamab Oncology (9966.HK) Income Statement Analysis – Financial Results
- Zanite Acquisition Corp. (ZNTE) Income Statement Analysis – Financial Results
- Alta Equipment Group Inc. (ALTG) Income Statement Analysis – Financial Results
- LCTI Low Carbon Technologies International Inc. (LWCTF) Income Statement Analysis – Financial Results
- Qualitau Ltd (QLTU.TA) Income Statement Analysis – Financial Results
Evolent Health, Inc. (EVH)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.evolenthealth.com
About Evolent Health, Inc.
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.96B | 1.35B | 907.96M | 1.02B | 846.38M | 627.06M | 434.95M | 254.19M | 96.88M | 0.00 | 25.67M | 8.35M |
| Cost of Revenue | 1.50B | 1.04B | 657.55M | 701.37M | 513.06M | 327.83M | 269.35M | 155.18M | 57.40M | 0.00 | 30.02M | 11.27M |
| Gross Profit | 460.47M | 316.58M | 250.41M | 321.06M | 333.32M | 299.24M | 165.60M | 99.01M | 39.48M | 0.00 | -4.35M | -2.93M |
| Gross Profit Ratio | 23.45% | 23.42% | 27.58% | 31.40% | 39.38% | 47.72% | 38.07% | 38.95% | 40.75% | 0.00% | -16.93% | -35.08% |
| Research & Development | 0.00 | 27.00M | 15.50M | 15.10M | 19.80M | 18.20M | 17.20M | 11.10M | 5.80M | 0.00 | 2.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 358.11M | 269.27M | 219.50M | 310.55M | 392.82M | 306.31M | 205.67M | 160.69M | 75.29M | 0.00 | 15.60M | 15.98M |
| Other Expenses | 173.57M | 67.20M | 60.04M | 61.48M | 60.91M | 109.00K | 171.00K | 4.00K | 7.17M | -25.25M | 1.00K | 0.00 |
| Operating Expenses | 531.68M | 336.46M | 279.54M | 372.03M | 453.73M | 350.82M | 238.04M | 177.92M | 82.45M | -25.25M | 16.81M | 16.69M |
| Cost & Expenses | 2.04B | 1.37B | 937.09M | 1.07B | 966.79M | 678.65M | 507.39M | 333.09M | 139.85M | -25.25M | 46.83M | 27.96M |
| Interest Income | 5.26M | 1.37M | 407.00K | 3.16M | 3.99M | 3.44M | 1.66M | 0.00 | 0.00 | 0.00 | 0.00 | 18.00K |
| Interest Expense | 54.21M | 15.57M | 25.43M | 28.34M | 14.53M | 5.48M | 3.64M | 723.00K | 293.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.42M | 90.25M | 60.04M | 60.84M | 66.64M | 44.52M | 32.37M | 17.22M | 7.17M | 0.00 | 1.21M | 114.00K |
| EBITDA | -24.79M | 43.75M | 55.66M | -241.38M | -245.95M | -4.15M | -40.40M | -220.31M | -31.51M | -25.25M | -20.35M | -19.51M |
| EBITDA Ratio | -1.26% | 0.54% | 9.94% | 2.31% | -7.73% | -1.32% | -9.20% | 38.10% | -464.44% | 0.00% | -257.85% | -233.70% |
| Operating Income | -71.21M | -59.84M | 30.25M | -37.88M | -120.41M | -47.48M | -72.84M | -237.42M | -42.97M | -25.25M | -21.16M | -19.62M |
| Operating Income Ratio | -3.63% | -4.43% | 3.33% | -3.71% | -14.23% | -7.57% | -16.75% | -93.40% | -44.36% | 0.00% | -82.41% | -235.07% |
| Total Other Income/Expenses | -131.19M | -65.72M | 12.61M | -67.69M | -18.23M | -6.67M | -3.56M | -114.00K | 386.26M | -25.25M | 41.19M | 19.00K |
| Income Before Tax | -202.41M | -62.08M | -29.80M | -337.80M | -327.12M | -54.15M | -76.40M | -237.53M | 343.29M | -25.25M | 20.03M | -19.60M |
| Income Before Tax Ratio | -10.31% | -4.59% | -3.28% | -33.04% | -38.65% | -8.64% | -17.57% | -93.45% | 354.35% | 0.00% | 78.03% | -234.84% |
| Income Tax Expense | -89.37M | -43.38M | 483.00K | -3.55M | -21.54M | 40.00K | -6.64M | -10.76M | 23.48M | 0.00 | 8.00K | 337.00K |
| Net Income | -113.04M | -18.70M | -30.28M | -334.25M | -305.58M | -52.66M | -60.67M | -159.74M | 332.49M | -25.25M | 20.02M | -19.26M |
| Net Income Ratio | -5.76% | -1.38% | -3.34% | -32.69% | -36.10% | -8.40% | -13.95% | -62.84% | 343.21% | 0.00% | 78.00% | -230.81% |
| EPS | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 13.14 | -0.66 | 0.06 | -1.13K |
| EPS Diluted | -1.28 | -0.20 | -0.35 | -3.94 | -3.71 | -0.68 | -0.94 | -3.55 | 6.93 | -0.66 | 0.06 | -1.13K |
| Weighted Avg Shares Out | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.00M | 25.13M | 38.23M | 38.23M | 17.00K |
| Weighted Avg Shares Out (Dil) | 111.25M | 93.70M | 86.07M | 84.93M | 82.36M | 77.34M | 64.35M | 45.03M | 46.14M | 38.23M | 38.23M | 17.00K |
Evolent Adds Russell Glass, Headspace CEO, to Board of Directors
Evolent to Release Fourth Quarter 2023 Financial Results on Thursday, February 22, 2024
New Strong Buy Stocks for January 5th
How Much Upside is Left in Evolent Health (EVH)? Wall Street Analysts Think 59.66%
Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan
Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan
Wall Street Analysts See a 56.84% Upside in Evolent Health (EVH): Can the Stock Really Move This High?
Best Momentum Stocks to Buy for November 20th
Evolent Health, Inc. (EVH) Q3 2023 Earnings Call Transcript
Evolent Health (EVH) Surpasses Q3 Earnings and Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports